Crossref
EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA
Value in Health · 2026-06 · 29 (6) · S138
DOI: 10.1016/j.jval.2026.03.688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Jazmin Pinzon.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pinzon, J. (2026). EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA. Value in Health, 29(6), S138. https://doi.org/10.1016/j.jval.2026.03.688
Vancouver
Pinzon J. EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA. Value in Health. 2026;29(6):S138. doi:10.1016/j.jval.2026.03.688
BibTeX
@article{Pinzon2026,
author = {Pinzon, Jazmin},
title = {EE394 COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S138},
doi = {10.1016/j.jval.2026.03.688}
}
EUVIMED